News

Ophthalmologist offers pearls for use of technology in daily work.

According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% (XDEMVY) is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.

According to the companies, this partnership will leverage RetinAI's innovative digital health technologies and RCA's network of clinics to analyze real-world health clinical and imaging data.

Cochair Peter J. McDonnell, MD, highlights what this year’s conference will mean for clinicians and addresses the anticipated increased patient volume.

The company also provided an update on tarcocimab development program for the treatment of neovascular age-related macular degeneration and diabetic macular edema.

With lawsuits looming over the issue, the FDA has updated the label on Horizon Pharmaceutical’s drug for thyroid eye disease to include risks associated with hearing loss.

According to the company, Megan Baldwin, PhD, CEO of Opthea Ltd, will provide an overview of the company’s Phase 3 clinical program advancing OPT-302 for the treatment of wet AMD.

According to the University of Barcelona, the agreement between DBGen Ocular Genomics and Novartis will allow the accurate diagnostics of the genetic bases of these two pathologies to be conducted by mass sequencing of gene panels designed by the UB spin-off.

According to The Fred Hollows Foundation, an estimated $12 trillion could be added to global output by 2025 if the gender gap was closed in both the workforce and leadership.

Circumferential canaloplasty, trabeculotomy provide IOP control for 2 years

The surgery provides one of the largest investment returns of any disease intervention.

Cedars-Sinai research is the first to uncover disease-related changes to the cornea and to propose potential therapeutic approaches to correct diabetic wound healing.

Francesca Marassi, PhD, and her collaborators have received a $13 million National Institutes of Health grant to study misplaced calcified deposits that are a misunderstood factor in common diseases of aging, including age-related macular degeneration.

Faricimab is currently approved in more than 70 countries to treat nAMD and DME, with more than 1 million doses distributed globally, and Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists annual meeting in Seattle.

The American Society of Retina Specialists is holding its 2023 annual meeting July 28 through August 1 at the Seattle Convention Center in downtown Seattle.

For visual recovery to occur, there must be photoreceptors left that can be rescued.

Andrew Lee, MD, Andrew Carey, MD, and Elizabeth Fortin, MD, sit down on this episode of the NeuroOp Guru to discuss neuro-ophthalmology, interprofessional eConsults, and whether they provide timely and valuable guidance

Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of July 16, 2023.

Santen will receive an equity stake in Visiox as an upfront payment, and remains eligible to receive sales milestone payments, as well as royalties on net sales of omidenepag isopropyl ophthalmic solution in the United States.

New laser is designed to deliver low-energy treatment with ultrashort pulse duration.

According to the ASRS Research and Safety in Therapeutics Committee, ophthalmologists noted instances of intraocular inflammation (IOI) after the initial injection of pegcetacoplan.

Condition is linked to longer resolution times, worse outcomes

SriniVas R. Sadda, MD, discusses being president-elect of ARVO, as well as AI research being conducted at Doheny Eye Institute.

According to the company, the transaction includes U.S. and Canadian commercial rights to six therapeutics, including two non-prescription brands.

According to the company, initial interim Phase 2 efficacy data is expected to be presented in H1 2024. It also is expected to provide an update regarding Phase 3 pivotal trial plans in Q1 2024 after discussion with the FDA later this year.

A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.

Lens is stable in capsular bag, less sensitive to misalignment.